Bioprocessing
IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome immune profiling platform will be used to study cellular drivers of durable and protective immune response to the virus.
Union Therapeutics licenses COVID-19 tech from TFF
Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology in combination with niclosamide to focus on treatments for COVID-19.
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate
Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming months. Such collaboration could change the way that innovation and competition are viewed in the biopharmaceutical industry, according to a policy forum published in Science on August 13.  Discuss
Akeso granted FDA Fast Track designation for bispecific antibody
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Akeso for Ak104, a bispecific antibody, as a monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer.
Prometheus to develop antibody for IBD
Prometheus Biosciences has entered into an agreement with Dr. Falk Pharma for the development and commercialization of Pr600, a novel precision antibody, for the treatment of inflammatory bowel disease (IBD).
AGC expands partnership with Novavax in U.S.
AGC Biologics is expanding its relationship with Novavax by increasing manufacturing of Novavax's Matrix-M adjuvant for the COVID-19 vaccine candidate from its Seattle facility.
Bio-Techne releases new SARS recombinant antibody
Bio-Techne has launched a SARS-CoV-1/2 spike receptor-binding domain LlamaBody recombinant antibody that blocks the virus from binding to the host receptor, angiotensin-converting enzyme 2.
Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19.
SAB begins phase I trial of COVID-19 treatment
SAB Biotherapeutics has started a phase I trial evaluating SAB-185 for the treatment of COVID-19.
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a newly launched platform targeted at COVID-19 vaccine development.  Discuss
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
General Discussion
Topic Replies / Views Last Update
Childhood vaccines may help protect against COVID-19 mortality
by Ratcatcher
0 / 6 More than 3 days ago
by Ratcatcher
https://academic.oup.com/ve/pages/coronavirus-evolution
by Michael
0 / 49 More than 3 days ago
by Michael
PopSci Hails Impossible Burger 2.0 as Most Important Engineering Innovation in 2019
by Mahesh Gupta
0 / 14 More than 3 days ago
by Mahesh Gupta
Engineered Bacteria Produces BeeFree Honey
by Mahesh Gupta
0 / 13 More than 3 days ago
by Mahesh Gupta
Consumers' Preference to Buy Unlabeled Produce Increases after Exposure to GMO-labeled Pro
by Mahesh Gupta
0 / 15 More than 3 days ago
by Mahesh Gupta
To see more posts from our community or to share a post of your own, go to our community's forum page.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter